Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Crinetics Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Disposition to issuer · Disposed 58,286 · Balance 79,650 F1: Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan. F2: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 2 · 2026-09-01 · Disposition to issuer · Disposed 79,650 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2028-03-16 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Disposition to issuer · Disposed 90,514 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.28 · Expires 2028-05-24 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-01 · Disposition to issuer · Disposed 74,540 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.19 · Expires 2029-03-08 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-01 · Disposition to issuer · Disposed 56,250 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.61 · Expires 2030-02-24 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Disposition to issuer · Disposed 60,000 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.29 · Expires 2031-02-26 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Disposition to issuer · Disposed 85,000 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.19 · Expires 2031-09-10 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2032-02-29 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Disposition to issuer · Disposed 77,000 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2033-02-28 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Disposition to issuer · Disposed 110,000 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.51 · Expires 2034-03-03 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Disposition to issuer · Disposed 87,000 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.86 · Expires 2035-02-19 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Disposition to issuer · Disposed 65,000 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.79 · Expires 2036-02-23 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Disposition to issuer · Disposed 47,000 · Balance 0 F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.
F2: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
F3: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
F4: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.
F5: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 3, 2023 21:38 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 23,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015578 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,289 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $19.59 | $61,238.34 |
DisclosureSEC source: 0001209191-23-006872 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,689 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:26 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 8,336 | $21.07 | $175,639.52 |
DisclosureSEC source: 0001209191-23-005252 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,815 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $21.07 per share. The range of sales prices on the transaction date was $21.00 to $21.08 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:28 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $18.00 | $56,268.00 |
DisclosureSEC source: 0001209191-23-004021 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,151 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:23 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $18.35 | $57,362.10 |
DisclosureSEC source: 0001209191-23-001846 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,277 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 22:11 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $16.00 | $50,016.00 |
DisclosureSEC source: 0001209191-22-061986 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,403 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · balance_after: Includes 561 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2022 by the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:28 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $17.84 | $55,767.84 |
DisclosureSEC source: 0001209191-22-059779 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,968 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:46 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $18.72 | $58,518.72 |
DisclosureSEC source: 0001209191-22-057585 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,094 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:35 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $18.52 | $57,893.52 |
DisclosureSEC source: 0001209191-22-055522 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,220 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 21:34 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $17.73 | $55,423.98 |
DisclosureSEC source: 0001209191-22-054104 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,346 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:40 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $19.64 | $61,394.64 |
DisclosureSEC source: 0001209191-22-052769 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,472 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:40 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 4,168 | $21.01 | $87,569.68 |
DisclosureSEC source: 0001209191-22-050529 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,598 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:20 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 1,042 | $21.00 | $21,883.77 |
DisclosureSEC source: 0001209191-22-049311 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,766 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:20 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,126 | $18.59 | $58,112.34 |
DisclosureSEC source: 0001209191-22-048734 · doc4.xml · nonDerivative · entry 2 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,808 F2 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| May 20, 2022 Filed Sep 6, 2022 20:20 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,336 | $11.02 | $14,722.72 |
DisclosureSEC source: 0001209191-22-048734 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,934 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,247 | $20.10 | $65,251.71 |
DisclosureSEC source: 0001209191-22-027145 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,598 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.096 per share. The range of sales prices on the transaction date was $20.06 to $21.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| April 18, 2022 Filed Apr 21, 2022 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 5,664 | $25.81 | $146,187.84 |
DisclosureSEC source: 0001209191-22-025190 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,845 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 23:08 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 9,000 | $23.97 | $215,761.50 |
DisclosureSEC source: 0001209191-22-023556 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,509 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $23.9735 per share. The range of sales prices on the transaction date was $23.9515 to $24.0027 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 21:39 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 4,164 | $21.80 | $90,775.20 |
DisclosureSEC source: 0001209191-22-022036 · doc4.xml · nonDerivative · entry 2 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,509 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:39 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 4,164 | $21.06 | $87,699.67 |
DisclosureSEC source: 0001209191-22-022036 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,673 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $21.0614 per share. The range of sales prices on the transaction date was $21.0201 to $21.0774 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:33 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,123 | $18.94 | $59,149.62 |
DisclosureSEC source: 0001209191-22-019595 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,837 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 3,123 | $19.73 | $61,616.79 |
DisclosureSEC source: 0001209191-22-015130 · doc4.xml · nonDerivative · entry 2 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,960 F2 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0001209191-22-015130 · doc4.xml · derivative · entry 3 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2032-02-27 F3 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015130 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,083 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:34 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 3,123 | $18.64 | $58,212.72 |
DisclosureSEC source: 0001209191-22-010784 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,583 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 3,123 | $18.79 | $58,681.17 |
DisclosureSEC source: 0001209191-22-006797 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,706 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · balance_after: Includes 954 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2021 by the Reporting Person. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:47 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 4,168 | $23.29 | $97,072.72 |
DisclosureSEC source: 0001209191-22-004051 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,875 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 21:37 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 7,168 | $28.02 | $200,847.36 |
DisclosureSEC source: 0001209191-22-002197 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,043 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 00:19 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 3,000 | $27.95 | $83,851.80 |
DisclosureSEC source: 0001209191-21-071646 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,211 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.9506 per share. The range of sales prices on the transaction date was $27.950 to $27.952 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:28 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 5,668 | $24.14 | $136,825.52 |
DisclosureSEC source: 0001209191-21-070272 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,211 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:36 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 5,668 | $27.38 | $155,189.84 |
DisclosureSEC source: 0001209191-21-067840 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,879 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 1,500 | $27.97 | $41,955.00 |
DisclosureSEC source: 0001209191-21-065149 · doc4.xml · nonDerivative · entry 2 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,547 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 5,668 | $26.75 | $151,619.00 |
DisclosureSEC source: 0001209191-21-065149 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,047 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 22:44 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 3,900 | $28.42 | $110,845.80 |
DisclosureSEC source: 0001209191-21-063679 · doc4.xml · nonDerivative · entry 2 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,715 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $28.422 per share. The range of sales prices on the transaction date was $28.340 to $28.500 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:44 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 12,600 | $27.95 | $352,195.20 |
DisclosureSEC source: 0001209191-21-063679 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,615 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.952 per share. The range of sales prices on the transaction date was $27.950 to $27.959 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:57 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 5,668 | $24.79 | $140,509.72 |
DisclosureSEC source: 0001209191-21-062731 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,215 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 3,000 | $24.00 | $71,991.00 |
DisclosureSEC source: 0001209191-21-061915 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,883 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $23.997 per share. The range of sales prices on the transaction date was $23.970 to $24.003 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 20:28 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 1,042 | $21.10 | $21,983.60 |
DisclosureSEC source: 0001209191-21-061496 · doc4.xml · nonDerivative · entry 1 Betz Stephen F. · CIK 0001886575 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,883 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.